CO6480962A2 - Anticuerpos anti-vegf y sus usos - Google Patents
Anticuerpos anti-vegf y sus usosInfo
- Publication number
- CO6480962A2 CO6480962A2 CO11179622A CO11179622A CO6480962A2 CO 6480962 A2 CO6480962 A2 CO 6480962A2 CO 11179622 A CO11179622 A CO 11179622A CO 11179622 A CO11179622 A CO 11179622A CO 6480962 A2 CO6480962 A2 CO 6480962A2
- Authority
- CO
- Colombia
- Prior art keywords
- cdr
- bevacizumab
- ranibizumab
- cdrs
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente divulgación se refiere a variantes del anticuerpo anti-VEGF bevacizumab con inmunogenicidad reducida y/o afinidad mejorada hacia VEGF, en comparación con bevacizumab o ranibizumab. Bevacizumab tiene tres CDRs de la cadena pesada, denominadas aquí (en orden desde el terminal amino al carboxi) CDR-H1, CDR-H2 y CDR-H3, y tres CDRs de la cadena liviana, denominadas aquí (en orden desde el terminal amino al carboxi) CDR-L1, CDR-L2 y CDR-L3. Las secuencias de las CDRs de bevacizumab se muestran en las Figuras 1A y 1B, y su numeración se presenta en la Tabla 1 (para las CDRs de la cadena pesada) y la Tabla 2 (para las CDRs de la cadena liviana). Un anticuerpo relacionado, ranibizumab, fue generado por maduración de la afinidad de bevacizumab. Ranibizumab tiene las secuencias de CDR-L1, CDR-L2, CDR-L3 y CDR-H2 idénticas a bevacizumab, pero varía en sus secuencias de CDR-H1 y CDR-H3 de las de bevacizumab. Las secuencias de las cadenas pesada y liviana de ranibizumab se muestran en la Figura 1C, y las CDRs se presentan en la Figura 1D.Los anticuerpos de la divulgación generalmente tienen al menos una sustitución de amino ácido en al menos una CDR de la cadena pesada en comparación con bevacizumab y ranibizumab.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21800509P | 2009-06-17 | 2009-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6480962A2 true CO6480962A2 (es) | 2012-07-16 |
Family
ID=42543312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11179622A CO6480962A2 (es) | 2009-06-17 | 2011-12-28 | Anticuerpos anti-vegf y sus usos |
Country Status (25)
Country | Link |
---|---|
US (1) | US9079953B2 (es) |
EP (2) | EP2894167B1 (es) |
JP (1) | JP5785941B2 (es) |
KR (1) | KR20120034739A (es) |
CN (1) | CN102482349B (es) |
AU (1) | AU2010262836B2 (es) |
BR (1) | BRPI1012321A8 (es) |
CA (1) | CA2765755C (es) |
CL (1) | CL2011003182A1 (es) |
CO (1) | CO6480962A2 (es) |
CR (1) | CR20110653A (es) |
EC (1) | ECSP12011584A (es) |
ES (2) | ES2534355T3 (es) |
GT (1) | GT201100326A (es) |
HK (1) | HK1211961A1 (es) |
IL (2) | IL216835A0 (es) |
MX (2) | MX2011013781A (es) |
NZ (1) | NZ596837A (es) |
PE (1) | PE20120622A1 (es) |
RU (1) | RU2567639C2 (es) |
SG (2) | SG10201403327WA (es) |
TW (1) | TWI510248B (es) |
UA (1) | UA104626C2 (es) |
WO (1) | WO2010148223A2 (es) |
ZA (1) | ZA201109098B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
EP2670778A1 (en) * | 2011-02-02 | 2013-12-11 | Glaxo Group Limited | Novel antigen binding proteins |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
MX347771B (es) | 2011-04-12 | 2017-05-12 | Gangagen Inc | Polipeptidos antibacterianos quimericos. |
MY183712A (en) | 2012-07-13 | 2021-03-09 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
KR102123134B1 (ko) * | 2012-09-19 | 2020-06-15 | 제넨테크, 인크. | 단백질로의 노르류신 오혼입을 방지하기 위한 방법 및 조성물 |
WO2014052713A2 (en) | 2012-09-27 | 2014-04-03 | Massachusetts Institute Of Technology | Her2-and vegf-a-binding proteins with enhanced stability |
KR101279895B1 (ko) * | 2012-10-24 | 2013-06-28 | 주식회사 진흥기공 | 유체 이송용 덕트에 결합 사용되는 댐퍼의 이중 브레이드 밀폐 장치 |
US20140154255A1 (en) * | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
CN105188749B (zh) | 2012-12-21 | 2017-12-19 | 西雅图基因公司 | 抗ntb‑a抗体及相关组合物和方法 |
US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
CA2911087A1 (en) * | 2013-04-30 | 2014-11-06 | Harish Shandilya | Novel cloning, expression & purification method for the preparation of ranibizumab |
SG10201708882TA (en) * | 2013-07-12 | 2017-12-28 | Ophthotech Corp | Methods for treating or preventing ophthalmological conditions |
DK3041513T3 (da) | 2013-09-08 | 2020-10-26 | Kodiak Sciences Inc | Zwitterioniske faktor viii-polymerkonjugater |
JP6983511B2 (ja) | 2014-04-25 | 2021-12-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脳中の転移乳癌および他の癌を処置するための方法および組成物 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
JP7012432B2 (ja) * | 2014-07-14 | 2022-01-28 | 中外製薬株式会社 | タンパク質のエピトープを同定するための方法 |
KR102210104B1 (ko) | 2014-10-17 | 2021-02-01 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
CN108148134B (zh) * | 2015-01-06 | 2020-06-12 | 珠海亿胜生物制药有限公司 | 抗vegf抗体 |
AU2016381964B2 (en) * | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
US20190127455A1 (en) * | 2016-04-15 | 2019-05-02 | Regenxbio Inc. | Treatment of Ocular Diseases with Fully- Human Post-Translationally Modified Anti-VEGF Fab |
KR102574810B1 (ko) * | 2016-04-15 | 2023-09-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 습성 연령 관련 황반 변성의 치료를 위한 조성물 |
CN106039309B (zh) * | 2016-06-30 | 2024-04-19 | 中国人民解放军总医院第一附属医院 | 用于治疗恶性肿瘤造成的胸腔积液的药物组合物及其应用 |
JP2021506861A (ja) | 2017-12-19 | 2021-02-22 | アコーオス インコーポレイテッド | 内耳への治療用抗体のaav媒介送達 |
US20200115443A1 (en) * | 2018-10-12 | 2020-04-16 | Trican Biotechnology Co., Ltd | Bi-functional fusion proteins and uses thereof |
CN111423512B (zh) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN111363038A (zh) * | 2020-03-26 | 2020-07-03 | 北京纽安博生物技术有限公司 | 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用 |
CN111808191A (zh) * | 2020-05-11 | 2020-10-23 | 廊坊天光生物技术有限公司 | 一种用于检测血清中vegf含量的抗体对及其用途 |
KR20230117179A (ko) | 2020-12-01 | 2023-08-07 | 아카우오스, 인크. | 청신경초종 연관 증상을 치료하기 위한 항-vegf 항체작제물 및 관련된 방법 |
WO2022183418A1 (zh) * | 2021-03-04 | 2022-09-09 | 百奥泰生物制药股份有限公司 | 抗vegf抗体制剂 |
WO2023150142A1 (en) | 2022-02-02 | 2023-08-10 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
NZ500077A (en) | 1997-04-07 | 2001-10-26 | Genentech Inc | Humanized antibodies to vascular endothelial growth factor (VEGF) and methods for their preparation. |
ATE200679T1 (de) | 1997-04-14 | 2001-05-15 | Micromet Ag | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP1950300A3 (en) | 1998-11-18 | 2011-03-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
ES2301254T3 (es) | 1998-11-18 | 2008-06-16 | Genentech, Inc. | Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales. |
JP4731016B2 (ja) | 1998-12-22 | 2011-07-20 | ジェネンテック, インコーポレイテッド | 血管内皮細胞増殖因子アンタゴニストとその用途 |
US6979559B2 (en) | 2000-10-12 | 2005-12-27 | Marical, Inc. | Polyvalent cation-sensing receptor in atlantic salmon |
DE60117601T2 (de) | 2000-12-14 | 2006-11-16 | Genentech Inc., San Francisco | Bakterielle wirtstämme |
US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
DK1356052T3 (da) | 2000-12-14 | 2008-12-08 | Genentech Inc | Produktion af hele antistoffer i prokaryotiske celler |
CA2369893A1 (en) | 2001-02-12 | 2002-08-12 | Warner-Lambert Company | Vegf responsive cell-based assay for determining vegf bioactivity |
US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
US20040010376A1 (en) | 2001-04-17 | 2004-01-15 | Peizhi Luo | Generation and selection of protein library in silico |
US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
EP1573002A4 (en) | 2002-02-11 | 2008-07-16 | Genentech Inc | ANTIBODY VARIANTS WITH ACCELERATED ANTIGEN ASSOCIATED SPEEDS |
WO2003099999A2 (en) * | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CA2499300A1 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
ME00425B (me) | 2003-05-30 | 2011-10-10 | Genentech Inc | Liječenje sa anti-vegf antitijelima |
SI1648940T1 (sl) | 2003-07-28 | 2016-08-31 | Genentech, Inc. | Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A |
KR101192496B1 (ko) | 2003-11-06 | 2012-10-18 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
NZ554481A (en) | 2004-10-12 | 2010-04-30 | Amprotein Corp | Fusion protein that binds to IL-1 receptor and one of IL18, IL4 or IL13 |
RU2007117716A (ru) | 2004-10-12 | 2008-11-20 | Ампротеин Корпорейшн (Us) | Химерный белок |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
US20080207467A1 (en) | 2005-03-03 | 2008-08-28 | Xencor, Inc. | Methods for the design of libraries of protein variants |
EP1966374B1 (en) | 2005-11-14 | 2013-02-13 | Bioren, Inc. | Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening |
WO2007059336A1 (en) | 2005-11-18 | 2007-05-24 | Nextrom Oy | Method and apparatus for manufacturing water-free optical fiber preforms |
US7820165B2 (en) | 2005-11-21 | 2010-10-26 | Merck Serono, S.A. | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
AU2007208340B2 (en) | 2006-01-23 | 2012-11-01 | Joseph P. Errico | Methods and compositions of targeted drug development |
EP3093026B1 (en) | 2006-07-10 | 2020-07-01 | ESBATech, an Alcon Biomedical Research Unit LLC | Scfv antibodies which pass epithelial and/or endothelial layers |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
CA2691692C (en) | 2007-07-09 | 2021-05-18 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP2280997A2 (en) | 2008-04-18 | 2011-02-09 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
-
2010
- 2010-06-17 AU AU2010262836A patent/AU2010262836B2/en not_active Ceased
- 2010-06-17 EP EP14197237.2A patent/EP2894167B1/en not_active Not-in-force
- 2010-06-17 CN CN201080027121.5A patent/CN102482349B/zh not_active Expired - Fee Related
- 2010-06-17 KR KR1020127001157A patent/KR20120034739A/ko not_active Application Discontinuation
- 2010-06-17 PE PE2011002096A patent/PE20120622A1/es not_active Application Discontinuation
- 2010-06-17 EP EP10725590.3A patent/EP2443150B1/en active Active
- 2010-06-17 MX MX2011013781A patent/MX2011013781A/es active IP Right Grant
- 2010-06-17 ES ES10725590.3T patent/ES2534355T3/es active Active
- 2010-06-17 SG SG10201403327WA patent/SG10201403327WA/en unknown
- 2010-06-17 BR BRPI1012321A patent/BRPI1012321A8/pt not_active IP Right Cessation
- 2010-06-17 US US12/817,800 patent/US9079953B2/en not_active Expired - Fee Related
- 2010-06-17 WO PCT/US2010/039029 patent/WO2010148223A2/en active Application Filing
- 2010-06-17 CA CA2765755A patent/CA2765755C/en not_active Expired - Fee Related
- 2010-06-17 MX MX2014001638A patent/MX346002B/es unknown
- 2010-06-17 TW TW099119749A patent/TWI510248B/zh not_active IP Right Cessation
- 2010-06-17 NZ NZ596837A patent/NZ596837A/en not_active IP Right Cessation
- 2010-06-17 SG SG2011093473A patent/SG177265A1/en unknown
- 2010-06-17 UA UAA201114515A patent/UA104626C2/ru unknown
- 2010-06-17 RU RU2011150916/10A patent/RU2567639C2/ru not_active IP Right Cessation
- 2010-06-17 ES ES14197237.2T patent/ES2656446T3/es active Active
- 2010-06-17 JP JP2012516307A patent/JP5785941B2/ja not_active Expired - Fee Related
-
2011
- 2011-12-06 CR CR20110653A patent/CR20110653A/es unknown
- 2011-12-07 IL IL216835A patent/IL216835A0/en not_active IP Right Cessation
- 2011-12-09 ZA ZA2011/09098A patent/ZA201109098B/en unknown
- 2011-12-15 CL CL2011003182A patent/CL2011003182A1/es unknown
- 2011-12-16 GT GT201100326A patent/GT201100326A/es unknown
- 2011-12-28 CO CO11179622A patent/CO6480962A2/es not_active Application Discontinuation
-
2012
- 2012-01-09 EC ECSP12011584 patent/ECSP12011584A/es unknown
-
2015
- 2015-06-23 IL IL239604A patent/IL239604A/en not_active IP Right Cessation
- 2015-12-30 HK HK15112838.4A patent/HK1211961A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6480962A2 (es) | Anticuerpos anti-vegf y sus usos | |
CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
AR080501A1 (es) | Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1) | |
MX2018014714A (es) | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. | |
NZ603045A (en) | Tnf-alpha binding proteins | |
ES2721753T3 (es) | Anticuerpos contra IL-6 y usos de los mismos | |
PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
UA108466C2 (en) | Antibody antagonises c-Met | |
CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu | |
NZ613716A (en) | Novel antibodies inhibiting c-met dimerization, and uses thereof | |
AR097651A1 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
NZ593853A (en) | ANTI-cMET ANTIBODY | |
NZ599761A (en) | Engineered anti-tslp antibody | |
AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
AR088579A1 (es) | Formulaciones de anticuerpos | |
PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
PE20040947A1 (es) | MOLECULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA | |
RU2017145268A (ru) | Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
NZ599779A (en) | Compositions and methods for treating inflammatory disorders | |
PE20191075A1 (es) | Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |